"....After many years of disappointing results for women with ovarian cancer, on the eve of World Cancer Day on Feb 4, 2012, there is at long last an opportunity to celebrate some improvements made in the diagnosis and treatment of this devastating cancer (notably Avastin). World Cancer Day will undoubtedly be dominated by the more prominent cancer types, but it is imperative that continued efforts are made in rarer cancers and that these diseases are not ophaned by a disproportionate focus on easy wins. Major advances into breaking the silence are long overdue.
Showing posts with label lancet oncology. Show all posts
Showing posts with label lancet oncology. Show all posts
Wednesday, February 22, 2012
Monday, January 30, 2012
open access: Editorial - Ovarian cancer: breaking the silence : The Lancet Oncology (references Avastin studies and NEJM)
Ovarian cancer: breaking the silence
"The
heterogeneous nature of cancer makes it a very difficult disease to
manage. Although great progress has been made against many types of
cancer (as highlighted by recent mortality data from the American Cancer Society), treatment of others has shown little change
in the past few decades. Ovarian cancer, for example, has traditionally
lagged behind: recent research, however, is starting to provide a
better outlook for women with this cancer. Two phase 3 clinical trials
published in December, 2011, in the New England Journal of Medicine (GOG018 and ICON7)
showed that women with newly diagnosed advanced ovarian cancer given
concomitant bevacizumab with a paclitaxel and carboplatin chemotherapy
regimen following surgery, and then maintenance bevacizumab, had
significantly longer progression-free survival compared with those who
received chemotherapy alone. On the basis of these results, on Dec 19,
2011, the European Medicines Agency approved bevacizumab for first-line
treatment of ovarian cancer, although it is uncertain whether the US FDA
will follow suit....."
"Ovarian cancer is the seventh most common cancer in women worldwide, with nearly a quarter of a million women diagnosed every year. 5-year survival is just 30%, a figure that has not changed for the past 30 years—this contrasts with breast cancer, in which 5-year survival has improved from 50% to 80% over the same period."
"Ovarian cancer is the seventh most common cancer in women worldwide, with nearly a quarter of a million women diagnosed every year. 5-year survival is just 30%, a figure that has not changed for the past 30 years—this contrasts with breast cancer, in which 5-year survival has improved from 50% to 80% over the same period."
Subscribe to:
Posts
(
Atom
)
